相关实验视频

Updated: Sep 13, 2025

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

系统性审查和二次治疗失败和免疫因子性的meta-analysis与肉毒神经毒素A在多个迹象

Uwe Walter^1,2, Phillipp Albrecht^3,4, Warner Carr⁵

¹Department of Neurology, Rostock University Medical Center, Rostock, Germany.

European journal of neurology

|July 29, 2025

概括

与其他肉毒神经毒素A (BoNT-A) 配方相比,肉毒神经毒素A可能会降低二次治疗失败 (STF) 和中和抗体 (NAbs) 的风险. 这一发现对于患有宫 dystonia,性或需要更高剂量的白发作的患者至关重要.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

玻尿酸神经毒素A (BoNT-A) 是治疗宫性 dystonia (CD),性和白的关键治疗方法.
中和抗体 (NAbs) 的发展可以导致一些患者的二次治疗失败 (STF).
调查STF和NAb阳性的配方特定发病率对于优化治疗结果至关重要.

研究的目的:

系统地审查和元分析三种商业BoNT-A配方中STF和NAb阳性的发生率.
为了比较abobotulinumtoxinA,incobotulinumtoxinA和onabotulinumtoxinA在患有CD,性或白性的患者中的免疫性潜力和疗效.

主要方法:

从PubMed,Embase和Google Scholar获得的研究的系统审查和元分析.
包括在特定的BoNT-A配方治疗后报告STF和/或NAb阳性的研究.
分析数据,分层分别按适应症 (CD,性,白血) 和BoNT-A类型进行分析.

主要成果:

与abobotulinumtoxinA和onabotulinumtoxinA相比,incobotulinumtoxinA显示的患有STF和NAbs的患者比例明显较低,用于CD和性.
较高的abobotulinumtoxinA或onabotulinumtoxinA的平均剂量与数值较高的NAb阳性患者比例相关.
没有观察到免疫性STF或持久NAbs的病例,这些病例在仅用incobotulinumtoxinA治疗的患者中没有观察到.

结论:

发展STF和NAbs的风险取决于配方,并因适应症而异.
毒素A可能是减轻STF和免疫原性的首选选择,特别是对于需要更高剂量或重复治疗的患者.
考虑BoNT-A配方对于神经运动障碍的长期治疗成功和安全至关重要.

关键词:

这是一种白性动 (blepharospasm).肉毒毒素是一种毒素.宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 宫性 dystonia 免疫性免疫性免疫性性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性,性等.

更多相关视频

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

相关概念视频

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...